Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095965 | 0.85 | HSD11B1 (0.72) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5104510 | 0.80 | HSD11B1 (0.77) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5092252 | 0.79 | HSD11B1 (0.53) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5098640 | 0.78 | HSD11B1 (0.60) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5104713 | 0.78 | HSD11B1 (1.00) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5092201 | 0.78 | HSD11B1 (0.60) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5104778 | 0.77 | HSD11B1 (0.51) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL611826 | 0.76 | HSD11B1 (0.58) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5104704 | 0.76 | HSD11B1 (0.46) | HSD11B1GAARAB9AHSD17B1MEN1 | |
| SCHEMBL5098014 | 0.76 | HSD11B1 (0.50) | HSD11B1GAARAB9AHSD17B1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | FONG TUNG M (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1474139-A4 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1482794-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1474139-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | MERCK & CO., INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | MERCK & CO., INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | MERCK & CO., INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2003075660-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | MERCK & CO., INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003065983-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122033-A1 | Combination therapy for the treatment of obesity | GPR119, GIPR, FABP6 | HSD11B1 611/4885GAA 72/4885RAB9A 3363/4885 |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885GAA 1127/4885RAB9A 4415/4885 |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | CNR1, HSD11B1, HSD17B1 | HSD11B1 2/4885GAA 2286/4885RAB9A 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.